A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo ) in Subjects with Recurrent or Progressive Glioblastoma
Brief description of study
The purpose of this research study is to evaluate the safety and tolerability of intratumorally injected Ad-RTS-hIL-12 combined with oral veledimex, a viral gene therapy, in combination with cemiplimab-rwlc, a PD-1 inhibitor, in patients with recurrent glioblastoma.
Clinical Study Identifier: s19-00086
ClinicalTrials.gov Identifier: NCT04006119
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
